Given the exorbitant cost of #spinalsurgery procedures and the associated #healthcare expenses, there is high demand for a #noninvasive off-the-shelf medication for SCI treatment, and $NRX is meeting just that market
https://t.co/ulmJ5gHLmJ
$HUB's $SPAC transaction with is expected to close in the third quarter of this year, so get excited to see this winner of #quantumcomputing on $NASDAQ very soon $RNER https://t.co/8Euv59ajzV
$NRX developing #exosome therapy for patients with SCI, has signed collaboration agreement with @Polyrizon, an Israeli #biotech company that specializes in innovative #intranasal products https://t.co/FO190BiGnz
$VEGA.CN is moving in the right direction, by expanding its #products and #partnerships. Company has reached significant milestones this year by clocking in stellar #revenuegrowth every month https://t.co/a36AZ6enWI